BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Uckun FM, Qazi S, Demirer T, Champlin RE. Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma. EBioMedicine 2019;39:612-20. [PMID: 30545798 DOI: 10.1016/j.ebiom.2018.12.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhang C, Sha Y, Liu H, Guo D, Jiang Y, Hong L, Shi L, Huang H. Type 2 diabetes mellitus does not increase the risk of multiple myeloma: a systematic review and meta-analysis. Transl Cancer Res 2020;9:2884-94. [PMID: 35117645 DOI: 10.21037/tcr.2020.03.36] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Bryant AR, Hilden P, Giralt S, Chung DJ, Maloy M, Landau H, Landgren O, Scordo M, Shah G, Smith EL, O'Reilly RJ, Perales MA, Koehne G. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant 2020;26:58-65. [PMID: 31493537 DOI: 10.1016/j.bbmt.2019.08.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kampa M, Notas G, Stathopoulos EN, Tsapis A, Castanas E. The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer. Front Oncol 2020;10:827. [PMID: 32612943 DOI: 10.3389/fonc.2020.00827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Von Suskil M, Sultana KN, Elbezanti WO, Al-Odat OS, Chitren R, Tiwari AK, Challagundla KB, Srivastava SK, Jonnalagadda SC, Budak-Alpdogan T, Pandey MK. Bruton's Tyrosine Kinase Targeting in Multiple Myeloma. Int J Mol Sci 2021;22:5707. [PMID: 34071917 DOI: 10.3390/ijms22115707] [Reference Citation Analysis]
5 Valent P, Orfao A, Kubicek S, Staber P, Haferlach T, Deininger M, Kollmann K, Lion T, Virgolini I, Winter G, Hantschel O, Kenner L, Zuber J, Grebien F, Moriggl R, Hoermann G, Hermine O, Andreeff M, Bock C, Mughal T, Constantinescu SN, Kralovics R, Sexl V, Skoda R, Superti-Furga G, Jäger U. Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. Hemasphere 2021;5:e536. [PMID: 33623882 DOI: 10.1097/HS9.0000000000000536] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tibullo D, Giallongo C, Romano A, Vicario N, Barbato A, Puglisi F, Parenti R, Amorini AM, Wissam Saab M, Tavazzi B, Mangione R, Brundo MV, Lazzarino G, Palumbo GA, Volti GL, Raimondo FD, Lazzarino G. Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells. Biomolecules 2020;10:E696. [PMID: 32365811 DOI: 10.3390/biom10050696] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
7 Uckun FM. Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma. Cancers (Basel) 2021;13:2018. [PMID: 33922005 DOI: 10.3390/cancers13092018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Čepulytė R, Žučenka A, Pečeliūnas V. Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation. Case Rep Hematol 2020;2020:8894031. [PMID: 33123389 DOI: 10.1155/2020/8894031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Wang B, Warden AR, Ding X. The optimization of combinatorial drug therapies: Strategies and laboratorial platforms. Drug Discov Today 2021:S1359-6446(21)00326-3. [PMID: 34332097 DOI: 10.1016/j.drudis.2021.07.023] [Reference Citation Analysis]
10 Gao M, Li C, Xiao H, Dong H, Jiang S, Fu Y, Gong L. hsa_circ_0007841: A Novel Potential Biomarker and Drug Resistance for Multiple Myeloma. Front Oncol 2019;9:1261. [PMID: 31803627 DOI: 10.3389/fonc.2019.01261] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
11 Liu M, Li L, Jin D, Liu Y. Nanobody-A versatile tool for cancer diagnosis and therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;13:e1697. [PMID: 33470555 DOI: 10.1002/wnan.1697] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
12 Uckun FM. Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma. Front Oncol 2021;11:760382. [PMID: 34858838 DOI: 10.3389/fonc.2021.760382] [Reference Citation Analysis]